hide-icon
First slide
Banner Image

Visit us at booth #1028 to explore our full portfolio of CytoCell® FISH probes, CytoSure® arrays and SureSeq™ NGS panels—powerful tools for gaining clear insights into haematological malignancies and more.

Together, we’ll ensure your lab has the specific genomic solutions it needs to tackle the complexity of haematological malignancy research and diagnosis.

Also be sure to check out our corporate workshop below to learn more about the SureSeq Myeloid MRD Panel!

 

Workshop

Harnessing NGS-based MRD detection: Insights from a retrospective AML cohort study

  • Date and Time: Wednesday, November 12, 2025 12:00 PM - 12:50 PM EST
  • Location: 156AB, Level 1
  • Corporate Workshop Speaker: Sean Glenn, PhD (he/him/his), Clinical Director, Genomics Shared Resource; Vice Chair, Molecular Pathology; Director, Advanced Molecular Diagnostics Laboratory, Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States

The emergence of NGS-based MRD technologies offers a significant advantage over existing approaches in haemato-oncology, simultaneously providing lower detection limits and deeper genomic insights.

Hear from Dr. Sean Glenn, Roswell Park Cancer Institute, as he shares his insights using the SureSeq Myeloid MRD Panel in a retrospective cohort study of research specimens collected from patients undergoing AML treatment.

Attendees will learn about the ability of the SureSeq Myeloid MRD Panel to assess residual disease signals as compared to other existing technologies in the field and how targeted NGS-based panels, combined with optimized bioinformatic analysis, can enhance our understanding of AML MRD.

CytoSure and SureSeq: For Research Use Only; Not for Use in Diagnostic Procedures. CytoCell: Product availability may vary from country to country and is subject to varying regulatory requirements. Please contact your local representatives for availability.